Therapy targeted to acid ceramidase reduced mortality post-myocardial infarction, a benefit attributed to the suppression of Cer20:0/Cer24:1, indicating the clinical value of precision therapy (69). The gene discussed is ASAH1; the disease is myocardial infarction.